Categories Earnings, Retail

What to expect when Best Buy (BBY) reports Q3 results

Best Buy Co. Inc. (NYSE: BBY) is scheduled to report third quarter 2020 earnings results on Tuesday, November 26, before the market opens. Analysts expect the company to report earnings of $1.03 per share on revenue of $9.7 billion.

Last quarter, the company’s domestic comparable sales benefited from strength in the appliances, tablets, headphones and services categories. Domestic comparable online revenue saw double-digit growth fueled by higher average order values and increased traffic.

Best Buy has been investing significantly to drive growth in its business and these investments are likely to benefit the quarterly results. The company’s cost-cutting measures are likely to help the bottom line numbers. However, negative impacts from foreign currency could hurt results.

In the second quarter of 2020, Best Buy beat earnings estimates but revenues fell short. Revenue rose 2% to $9.5 billion while adjusted EPS rose 19% to $1.08. Comparable sales increased 1.6%.

For the third quarter of 2020, enterprise revenue is expected to be $9.65 billion to $9.75 billion and comparable sales is expected to grow 0.5% to 1.5%. Adjusted EPS is expected to be $1.00 to $1.05.

Also read: Best Buy Q2 2020 Earnings Call Transcript

For the full year of 2020, the company expects enterprise revenue to come in the range of $43.1 billion to $43.6 billion. Enterprise comparable sales is estimated to grow 0.7-1.7%. Adjusted EPS is estimated to be $5.60 to $5.75.  

In September, Best Buy revealed its financial targets for fiscal year 2025. The company expects enterprise revenue of $50 billion and adjusted operating income rate of 5%. The retailer also expects to achieve $1 billion of additional cost reductions and efficiencies.

Shares of Best Buy have gained 37% year-to-date and 6% in the past three months.

Browse through our earnings calendar and get all scheduled earnings announcements, analyst/investor conference and much more!

Most Popular

Intensity Therapeutics is establishing a new field of localized cancer reduction: CEO

Intensity Therapeutics, Inc. (NASDAQ: INTS) is a clinical biotechnology company engaged in the discovery development, and commercialization of first-in-class cancer drugs that attenuate tumors with minimal side effects while training

INTU Earnings: Intuit Q1 2025 adj. profit rises on higher revenues

Financial technology company Intuit Inc. (NASDAQ: INTU) Thursday announced results for the first quarter of 2025, reporting a modest increase in adjusted earnings. The Mountain View-headquartered company’s first-quarter revenue came

Riding the AI wave, Nvidia looks set to stay on the high-growth path

After delivering strong results for the third quarter, Nvidia Corporation (NASDAQ: NVDA) this week said the launch of its new-generation Blackwell chip is on track. The company is thriving on

Add Comment
Loading...
Cancel
Viewing Highlight
Loading...
Highlight
Close
Top